AzTrials
AzTrials

Gastrointestinal MicrobiomeNCT06564285

The Effects of a Novel Nutritional Product on Nutrient Gaps and Gut Health in Adults With Occasional Gastrointestinal Issues

A study testing AG1 - Nutritional Supplement in people with Gastrointestinal Microbiome and Nutrition, Healthy, run by Athletic Greens International at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a randomized, double-blind, placebo-controlled study of N=40 adult men and women with occasional GI issues. This study to assess the effect of a novel dietary supplement on the gut microbiome, nutrient gaps, and tolerability. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
What is being tested?
AG1 - Nutritional Supplement
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
24 participants
Where
1 siteUnited States
Study dates
28 Aug 2024to 1 Feb 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

To be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provide voluntary signed and dated informed consent.
  • Does not have any chronic health conditions that could impact participation in this study such as oncological or psychiatric disorders.
  • No known history of chronic illness or disease.
  • Aged between 18 and 60 years (inclusive).
  • Body Mass Index of 20-34.9 (inclusive).
  • Agree to maintain existing dietary and physical activity patterns throughout the study period.
  • Willing and able to comply with the study protocol.
  • Self-reported gastrointestinal symptoms, such as self-reported abdominal pain, gas and bloating after meals, heartburn/acid reflux after meals, and issues with digestion.
  • Must be in good general health.
  • Following a stable, consistent diet pattern.
  • Agree to refrain from any lifestyle changes that may affect their GI tract and IBS symptoms for the duration of the study.
  • Not currently taking and not planning on introducing any product, supplement or medication aimed at gut health or nutritional gaps during the study period.
  • Resides in the United States.

An individual who meets the following criteria will be excluded from participation in this study:

  • Prior prescriptions for IBS or any other medication (OTC and prescription) targeting the gut.
  • Taking any supplements targeting the gut in the past 30 days.
  • Current IBS treatment (e.g. proton pump inhibitors, laxatives).
  • Follow an extreme diet intervention. This includes specific exclusion-type diets like vegan, vegetarian, carnivore, paleo, Atkins, ketogenic etc.
  • Experienced significant weight loss (10% total body weight) in the past 3 months prior to study participation.
  • Usage of any medication or herbal remedies which can affect the GI tract.
  • Food intolerances/allergies.
  • History of GI tract cancers.
  • Celiac disease/gluten intolerance.
  • Pregnant women, women trying to conceive, women less than 120 days postpartum, or nursing women.
  • Anyone with any allergy requiring the use of an Epi-pen.
  • Multivitamin/Multimineral supplement consumption within the past 3 months.
  • History of use of medications or dietary supplements known to confound the study or its endpoints.
  • History of unstable or new-onset cardiovascular, liver, or renal conditions.
  • History of diabetes or endocrine disorder.
  • Anyone who has received an antibiotic, antifungal, antiparasitic, or antiviral treatment within 90 days prior to the study.
  • Excessive alcohol consumption (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) within the past 6 months.
  • Current smokers or smoking within the past month.
  • History of drug abuse or dependence.
  • History of hyperparathyroidism or an untreated thyroid condition.
  • History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
  • Prior gastrointestinal bypass surgery (Lapband, etc.).
  • Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, IBS/IBD, diarrheal illnesses, history of colon resection, gastroparesis, and Inborn errors of metabolism (such as PKU).
  • Diagnosed chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's, ulcerative colitis, Lupus, HIV/AIDS, etc.).
  • Previous medical diagnosis of asthma, gout, or fibromyalgia.
  • A change in hormone therapy, including oral contraceptives, within 4 weeks prior to screening, or unwilling to maintain current hormone therapy/oral contraceptive use throughout the course of the study.
  • Known allergy or sensitivity to any ingredient in the test formulations as listed in the product label or in the placebo ingredients.
  • Currently participating in another research study with an investigational product or have been in another research study in the past 30 days or planning on taking part in another research study during this study's duration.
  • Has undergone any surgery or invasive treatments in the previous six months or has any planned for during the study period.
  • Anyone taking any supplements that have the same ingredients as those in the test product.
  • Has taken a probiotic, prebiotic, or postbiotic in the past 30 days.
  • Currently taking any opioid medications such as oxycodone (OxyContin®), hydrocodone (Vicodin®), codeine, morphine, or kratom.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Citruslabs

    Santa Monica, California, 90404-3727

Other trials in United States

About this study

This study is a randomized, double-blind, placebo-controlled study of N=40 adult men and women with occasional GI issues. This study to assess the effect of a novel dietary supplement on the gut microbiome, nutrient gaps, and tolerability.

Being tested
AG1 - Nutritional Supplement, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AG1 - Nutritional SupplementDietary supplement

    A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients

  • PlaceboDietary supplement

    Maltodextrin placebo

Study groups in NCT06564285
Study groupRoleWhat they receive
PlaceboPlacebo comparatorMaltodextrin + Flavoring
Receives: Dietary Supplement: Placebo
AG1 - Nutritional SupplementExperimentalA foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
Receives: Dietary Supplement: AG1 - Nutritional Supplement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gut Microbiome

    Examine changes in the gut microbiome via fecal metagenomics and metabolomics

    Measured: 14 days

Secondary outcomes (1)
  1. Nutrient Gaps

    Assess nutrient gaps by dietary record assessment utilizing The Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool

    Measured: 14 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2024
  2. Study start28 Aug 2024
  3. Primary completion1 Feb 2025
  4. Study completion1 Feb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Randomized, Double-Blind, Placebo Controlled Design
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06564285
Sponsor's protocol ID
AG-AG1-53-09
Status last verified
May 2025
First submitted
19 Aug 2024
Last updated
4 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing AG1 - Nutritional Supplement in people with Gastrointestinal Microbiome and Nutrition, Healthy, run by Athletic Greens International at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gut Microbiome (time frame: 14 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in